Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri scMRD Assay for AML. Learn More
X
Scientific presentation

Understanding the power of clonal heterogeneity in health and disease


Aaron Viny, MD, MS
Description

Immunohistochemistry (IHC) has been the gold standard to determine if a patient is in remission, but laboratories are transitioning into RT-PCR for fusions and flow cytometry for greater depth of response. However, clinicians are now moving away from algorithms to understand clonal architecture and mutation acquisition and trying their hand at newer technologies, such as single-cell DNA sequencing. Dr. Viny applies single-cell technology to examine clonal hematopoiesis and minimal residual disease (MRD) to better understand why some mutations are chemosensitive and others resistant to therapy.



VIEW


Scientific presentation
AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility
Aaron Llanso
AMP 2022 (2022)
Scientific presentation
Molecular Analysis of Acute Myeloid Leukemia in Morphologic Remission
Sanam Loghavi, MD
AMP 2022 (2022)
Scientific presentation
Considerations, Strategies, and Advances in Early Drug Development to Mitigate Clinical Holds and Achieve Successful CGT Outcomes
Azadeh Golipour, PhD, AVROBIO
J. Kelly Ganjei, AmplifyBio
Scott R. Burger, MD, Advanced Cell and Gene Therapy
Matthew Cato
(2022)
Scientific presentation
Overview on Mission Bio’s Applications
Simone Formisano
Mission Bio EU Heme Symposium (2022)
REQUEST QUOTE